Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC1 | P19801 | 9/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 9/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 4/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 4/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10188339 | 0.82 | LMNA (0.41) | AOC1AOC3RPS6KA3CYP2E1CYP2C8 | |
| SCHEMBL14485323 | 0.80 | RPS6KA3 (0.39) | AOC1AOC3RPS6KA3 | |
| SCHEMBL5106106 | 0.80 | RPS6KA3 (0.42) | AOC1AOC3RPS6KA3CYP2A6 | |
| SCHEMBL25467910 | 0.78 | CYP2E1 (0.41) | AOC1AOC3RPS6KA3CYP2E1CYP2C8 | |
| SCHEMBL20959793 | 0.77 | SLC6A2 (0.42) | AOC1AOC3RPS6KA3CYP2D6CYP2A6 | |
| SCHEMBL6118356 | 0.76 | RPS6KA3 (0.36) | AOC1AOC3RPS6KA3 | |
| SCHEMBL827231 | 0.76 | TDP1 (0.40) | AOC1AOC3RPS6KA3CYP2E1CYP2C8 | |
| SCHEMBL23685996 | 0.74 | RPS6KA3 (0.36) | AOC1AOC3RPS6KA3 | |
| SCHEMBL21652558 | 0.73 | AOC3 (0.38) | AOC1AOC3LOXL2 | |
| SCHEMBL269127 | 0.73 | RPS6KA3 (0.46) | AOC1AOC3RPS6KA3CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-05-07 | — | — | US | disclosed |
| US-20130231335-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8445503-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| WO-2011079114-A1 | PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | AOC1 3139/4885AOC3 2276/4885LOXL2 2334/4885 |
| US-20130231335-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | AOC1 3334/4885AOC3 2399/4885LOXL2 2404/4885 |
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | AOC1 3334/4885AOC3 2399/4885LOXL2 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.